Summary
This 8-K filing from AbbVie Inc. (ABBV) on January 27, 2017, primarily serves to announce their financial results for the fourth quarter and full year ended December 31, 2016. The report itself is brief, as it directs investors to a furnished press release (Exhibit 99.1) for the detailed financial outcomes and operational performance. This is a standard practice for companies to disseminate earnings information, providing investors with key metrics such as revenue, earnings per share, and potentially segment performance. Investors should review the referenced press release to understand AbbVie's performance in late 2016, which would include updates on their key products, pipeline developments, and any forward-looking guidance provided by management. The Chief Financial Officer, William J. Chase, signed off on the filing, indicating the CFO's attestation to the accuracy of the disclosed information within the press release. This filing is crucial for understanding the company's recent financial health and outlook.
Key Highlights
- 1AbbVie Inc. reported its financial results for the fourth quarter and full year ended December 31, 2016.
- 2The 8-K filing itself does not contain the detailed financial results but refers investors to a press release.
- 3Exhibit 99.1, a press release dated January 27, 2017, contains the actual financial and operational performance data.
- 4The filing is made pursuant to Item 2.02 of Form 8-K, which deals with Results of Operations and Financial Condition.
- 5William J. Chase, Executive Vice President and Chief Financial Officer, signed the report, indicating the official release of financial information.
- 6This report serves as a formal notification to the SEC and investors of the company's earnings announcement.